Kruti Acharya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kruti Acharya has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Lainie Friedman Ross
2 shared publicationsColleen Walsh Lang
1 shared publicationMichael E. Msall
Section of Developmental and Behavioral Pediatrics, Department of Pediatrics, University of Chicago Pritzker School of Medicine, JP Kennedy Research Center on Intellectual and Developmental Disabilities, Chicago, Illinois
1 shared publication- Michael E. Msall
Department of Pediatrics, University of Chicago, Chicago, USA
1 shared publication
Latest Publications
- 1 October 2017
- Published by SLACK, Inc. in Pediatric Annals
- Vol. 46 (10) , e358-e359
Health Care Disparities Among Children with Special Health Care Needs
- 1 October 2017
- Published by SLACK, Inc. in Pediatric Annals
- Vol. 46 (10) , e358-e359
Health Care Disparities Among Children with Special Health Care Needs
- 1 January 2011
- Published by Wiley in Developmental Disabilities Research Reviews
- Vol. 17 (1) , 27-31
Prenatal testing for intellectual disability: Misperceptions and reality with lessons from down syndrome
Down syndrome is the most common cause of intellectual disability. In the United States, it is recommended that prenatal testing for Down syndrome be offered to all women. Because of this policy and consequent public perception, having Down syndrome has become a disadvantage in the prenatal period. However, in the postnatal period, there may be some advantage in having Down syndrome. To help parents make informed decisions about screening and testing, it is crucial to reconcile divergent prenatal and postnatal perspectives. Advancements in genetic technologies will also impact the informed consent process and need to be considered. © 2012 Wiley Periodicals, Inc. Dev Disabil Res Rev 2011; 17:27–31.
- 1 January 2011
- Published by Wiley in Developmental Disabilities Research Reviews
- Vol. 17 (1) , 27-31
Prenatal testing for intellectual disability: Misperceptions and reality with lessons from down syndrome
Down syndrome is the most common cause of intellectual disability. In the United States, it is recommended that prenatal testing for Down syndrome be offered to all women. Because of this policy and consequent public perception, having Down syndrome has become a disadvantage in the prenatal period. However, in the postnatal period, there may be some advantage in having Down syndrome. To help parents make informed decisions about screening and testing, it is crucial to reconcile divergent prenatal and postnatal perspectives. Advancements in genetic technologies will also impact the informed consent process and need to be considered. © 2012 Wiley Periodicals, Inc. Dev Disabil Res Rev 2011; 17:27–31.
- Open Access
- 1 January 2011
- Published by Wiley in Developmental Disabilities Research Reviews
- Vol. 17 (1) , 1-2
Introduction: Bioethics and intelectual disability‐ scientific promise, social context and policy
- 1 January 2011
- Published by Wiley in Developmental Disabilities Research Reviews
- Vol. 17 (1) , 1-2
Open AccessIntroduction: Bioethics and intelectual disability‐ scientific promise, social context and policy
- 1 November 2009
- Published by Elsevier in Journal of the National Medical Association
- Vol. 101 (11) , 1163-1172
A Pilot Study to Explore Knowledge, Attitudes, and Beliefs about Sickle Cell Trait and Disease
- 1 November 2009
- Published by Elsevier in Journal of the National Medical Association
- Vol. 101 (11) , 1163-1172
A Pilot Study to Explore Knowledge, Attitudes, and Beliefs about Sickle Cell Trait and Disease
- 24 March 2009
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 149A (4) , 626-632
Fragile X screening: Attitudes of genetic health professionals
Although genetic health professionals (GHP) are major stakeholders in developing and implementing fragile X (FrX) testing and screening guidelines, their attitudes about FrX testing and population screening are virtually absent in the literature. A survey was conducted of physician geneticists (geneticists) and genetic counselors (GC). The survey addressed GHP's attitudes towards (1) prenatal FrX carrier screening; (2) pre‐ and full mutation screening of male and female newborns; (3) the single best time for FrX screening over the lifespan; and (4) their willingness to test a normally developing child with a positive family history. Surveys were completed by 30% (273/894) of eligible GHP. Attitudes of geneticists and GC were mostly indistinguishable. The single most favored screening approaches were (1) preconception screening targeted at women with a positive family history (43%); and (2) universal preconception screening (29%). While only 6% and 11% declared universal prenatal and universal newborn screening (NBS) as the ideal time respectively, 73% and 60% respectively would support such programs. GHP would design a NBS program to test male and female infants and to identify both pre‐ and full mutations. Over half would agree to order FrX testing on some normally developing children with a positive family history. In expanding FrX testing and screening to low risk individuals, GHP prefer preconception screening as the single best time. The majority also support prenatal screening and NBS. If NBS were to be introduced, GHP prefer screening to identify boys and girls with both pre‐ and full mutations.
- 24 March 2009
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 149A (4) , 626-632
Fragile X screening: Attitudes of genetic health professionals
Although genetic health professionals (GHP) are major stakeholders in developing and implementing fragile X (FrX) testing and screening guidelines, their attitudes about FrX testing and population screening are virtually absent in the literature. A survey was conducted of physician geneticists (geneticists) and genetic counselors (GC). The survey addressed GHP's attitudes towards (1) prenatal FrX carrier screening; (2) pre‐ and full mutation screening of male and female newborns; (3) the single best time for FrX screening over the lifespan; and (4) their willingness to test a normally developing child with a positive family history. Surveys were completed by 30% (273/894) of eligible GHP. Attitudes of geneticists and GC were mostly indistinguishable. The single most favored screening approaches were (1) preconception screening targeted at women with a positive family history (43%); and (2) universal preconception screening (29%). While only 6% and 11% declared universal prenatal and universal newborn screening (NBS) as the ideal time respectively, 73% and 60% respectively would support such programs. GHP would design a NBS program to test male and female infants and to identify both pre‐ and full mutations. Over half would agree to order FrX testing on some normally developing children with a positive family history. In expanding FrX testing and screening to low risk individuals, GHP prefer preconception screening as the single best time. The majority also support prenatal screening and NBS. If NBS were to be introduced, GHP prefer screening to identify boys and girls with both pre‐ and full mutations.